MedNews Week will be on the ground in New York City starting tomorrow for the 44th Annual Chemotherapy Foundation Symposium (#CFS2026)! 🗽
Led by Dr. Yan Leyfman, our team will be bringing you the latest insights, expert perspectives, and engaging conversations on emerging advances in cancer research and treatment.
Looking forward to seeing our team connect with leaders in oncology and share meaningful discussions with the global medical community.
Stay tuned for exclusive coverage from NYC!
@MedNewsWeek@YLeyfman@shahzeenkadir1@The_Noam_Levi@OncLive
#MedNewsWeek #Oncology #CFS2026
What if the next advance in transplantation is better care delivery, not just better therapies?
A pleasure to co-host Dr. @sghmd’s keynote on GVHD, PTCy & CAR-T access.
@oncodaily × @MedNewsWeek
https://t.co/pw4ZgF3amT
Thanks to Dr.@YLeyfman, Dr. @CParkMD & the @MedNewsWeek team!
🧬 94 allo-HCT recipients. 92.6% 1-year survival. Pharmaceutical costs per patient down >50% vs prior years. How? Two words: Systems redesign.
Want to dig deeper? Watch our @MedNewsWeek × @oncodaily keynote with Dr. Shernan Holtan (@sghmd)!
🎥 https://t.co/gbCfpYCRKe
Only 1 in 5 eligible patients receives transplantation or cellular therapy.
A striking access gap highlighted by Dr. @sghmd. Innovation must go hand in hand with access.
@MedNewsWeek x @oncodaily
https://t.co/4FPLQRBiVH
🧬 Beyond the Transplant
Better outcomes. Evolving GVHD management. Greater access to CAR-T.
Could rethinking the transplant system change what's possible for patients?
This week on @MedNewsWeek x @oncodaily hear from @sghmd Dr.Holtan
🎥 Watch: https://t.co/Ab5rFLIQoY
What if the next breakthrough in transplantation isn't a new therapy- but better care delivery? Dr. @sghmd explores GVHD, access & system redesign in this @MedNewsWeek × @oncodaily keynote.
Watch: https://t.co/Sd4ulVW9JQ
What if the effectiveness of a cancer nanovaccine depends not just on which antigen it delivers, but on how densely that antigen is displayed?
Nanovaccines can co-deliver tumor antigens and immune-stimulating adjuvants, but one design variable has received relatively little attention: antigen density.
In this study, researchers engineered an M13 bacteriophage-based nanovaccine and systematically varied the proportion of antigen displayed on its capsid, from approximately 6% to 70%.
The results revealed that antigen density influences more than antigen presentation. It also affects dendritic cell uptake, shaping the downstream CD8+ T-cell response.
In a mouse model of colorectal cancer (MC-38), optimizing antigen density increased neoantigen-specific CD8+ T-cell frequency by up to 7-fold, accompanied by significant tumor suppression.
The findings highlight an important design principle for cancer vaccines: optimizing the antigen itself may not be enough; how it is presented can be equally consequential.
M13 bacteriophage could offer a flexible platform for personalized cancer vaccines, although translating these findings from preclinical models into human studies remains an important next step.
#CancerImmunotherapy #CancerVaccines #Nanomedicine #Neoantigens #ImmunoOncology #TCells
https://t.co/DE2ZlbNieR
Dr. Shernan Holtan's @MedNewsWeek keynote explores how post-transplant cyclophosphamide (PTCy) has changed the donor-selection conversation in allogeneic transplantation.
Explore the full discussion: https://t.co/Q7PlcxvVdd
#Hematology#GVHD#PTCy#MedNewsWeek
Medical breakthroughs mean little if patients can’t access them. One of my key takeaways from Dr. @sghmd discussion at @MedNewsWeek was the need to bridge the gap between innovation and care delivery in stem cell transplantation.
🎥 Full discussion: https://t.co/JFHUKKVWm9
A great discussion on where the latest advances in MIBC fit into clinical practice, NIAGARA, EV/pembrolizumab, ctDNA, access to care, and the importance of mentorship in oncology. 🩺
An insightful look at how new evidence is shaping the field! 📹
CAR-T works. But how do we make it work better?
From earlier-line use to treatment resistance and next-generation therapies, where is CAR-T headed in aggressive B-cell lymphoma?
Dr. Abid explores what’s next in MedNews Week Medical Spotlight!🧬
Watch: https://t.co/2GtR3vymsn